Starpharma (OTCQX:SPHRY +8.7%) has completed additional antiviral testing for SPL7013 against SARS‑CoV-2 in lab studies conducted at Scripps Research Institute in the U.S.
The latest results confirm that when SPL7013 is applied at the concentration of the SPL7013 COVID-19 nasal spray, it has potent virucidal activity, inactivating more than 99.9% of SARS-CoV-2.
SPL7013 is a broad-spectrum antiviral, that inactivates viruses by blocking the interaction between viral surface proteins and the human cell receptor proteins.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.